ADC Therapeutics Getting $40M Investment
Astrazeneca Paying up to $440M for Payload Tech Firm Spirogen
By Nuala Moran
Wednesday, October 16, 2013
LONDON – Astrazeneca plc is taking a giant stride into antibody-drug conjugates (ADCs), acquiring payload technology company Spirogen plc for $200 million in cash, with a further $240 million to come in potential development milestones.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.